Gland Pharma Announces 48th AGM on August 25, 2026, via VC/OAVM
Gland Pharma Limited will hold its 48th Annual General Meeting on August 25, 2026, at 11:00 AM IST. The meeting will be conducted virtually via Video Conferencing/Other Audio-Visual Means. Financial statements for FY2025-26 will be shared electronically.
This is a standard procedural announcement for an upcoming AGM and does not directly impact the company's operations or financial standing in the short term.
The announcement is a routine corporate communication regarding the scheduling of the Annual General Meeting and does not contain any new financial performance data or strategic changes.
Gland Pharma Limited has announced that its 48th Annual General Meeting (AGM) is scheduled to be held on Tuesday, August 25, 2026, at 11:00 A.M. IST.
The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM), in compliance with SEBI regulations and Ministry of Corporate Affairs circulars. The deemed venue for the AGM is the company's corporate office.
In line with regulatory requirements, the Notice of the AGM, Standalone and Consolidated Financial Statements for the Financial Year 2025-26, along with the Board's Report and Auditor's Report, will be sent electronically to members whose email IDs are registered. For members who have not registered their email addresses or hold shares in physical mode, a communication with a weblink or QR code will be sent instead. Members are advised to register or update their email addresses and KYC details with the company's Registrar and Transfer Agent or their respective depository participants.
The AGM documents will also be available on the company's website and the websites of BSE, NSE, and NSDL. Members can join the AGM through the VC/OAVM facility or view the live webcast. Detailed guidelines for joining the AGM are provided in the Notice of the AGM.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.